Rovalpituzumab Tesirine
Other Neuroendocrine Carcinoma
AbbVieantibody_drug_conjugatePhase 1/2Dormant
CC
41/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 26/ 100
- Competitive Position
- 95/ 100
Competitive context
50 Active assets in the Other Neuroendocrine Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ETOPOSIDE National Cancer Institute (NCI) | Phase 2 | BB |
CIS-DIAMMINEDICHLOROPLATINUM II National Cancer Institute (NCI) | Phase 2 | B |
Everolimus AIO-Studien-gGmbH | Phase 2 | B |
Carboplatin Phanes Therapeutics | Phase 2 | B |
Octreotide Pamoate Novartis Pharmaceuticals | Phase 2 | B |
View all 50 →
Same molecule, other indications
Rovalpituzumab Tesirine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →